Dr Reddy's launches anti-ulcer capsules in US
Drug is generic equivalent of Zegerid capsules, which has a market of $307 million in twelve months to May 2016
 "Dr Reddy's launches anti-ulcer capsules in US")
The drug is the generic equivalent of Zegerid capsules in the US market, having been approved by the US Food and Drug Administration (USFDA).
The Zegerid brand and generic had US sales of approximately $306.7 million for the most recent twelve months ending in May, 2016, the company said citing the IMS Health data.
Zegerid is a registered trademark of Santarus, Inc. a wholly owned subsidiary of Salix Pharmaceuticals, Inc.
The product is used to treat gastric and duodenal ulcers among other related conditions.